| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Saluzzo, Francesca |
| dc.contributor.author | Espinosa-Pereiro, Juan |
| dc.contributor.author | Dressler, Stephan |
| dc.contributor.author | TAVORA DOS SANTOS FILHO, Ezio |
| dc.contributor.author | Seidel, Stephanie |
| dc.contributor.author | Gonzalez Moreno, Jesus |
| dc.contributor.author | SÁNCHEZ-MONTALVÁ, ADRIÁN |
| dc.date.accessioned | 2023-06-28T07:00:38Z |
| dc.date.available | 2023-06-28T07:00:38Z |
| dc.date.issued | 2023-05 |
| dc.identifier.citation | Saluzzo F, Espinosa-Pereiro J, Dressler S, Filho ETDS, Seidel S, Moreno JG, et al. Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience. Int J Infect Dis. 2023 May;130(Suppl1):S20–4. |
| dc.identifier.issn | 1201-9712 |
| dc.identifier.uri | https://hdl.handle.net/11351/9910 |
| dc.description | Community engagement; Tuberculosis research |
| dc.description.abstract | Objectives: Community representatives are key to ensuring that tuberculosis (TB) research is relevant, culturally sensitive, and appropriate. For all trials (new drugs or treatment regimens, diagnostics, or vaccines) this can result in improvement of recruitment, retention, and adherence to the trial schedule. The early engagement of the community will, later in time, support the process of implementation of new policies designed for successful products. We aim at developing a structured protocol for the early engagement of TB community representatives developed in the context of the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project.
Design: The EU-PEARL Innovative Medicine Initiative 2 (IMI2) project TB work package has developed a community engagement (CE) framework to ensure fair and efficient participation of the community in the design and implementation of TB clinical platform trials.
Results: We showed that early engagement of the EU-PEARL community advisory board highly contributes to the process of development of a community-acceptable Master Protocol Trial and Intervention-Specific Appendixes. We identified capacity building and training as major gaps in advancing CE in the TB field.
Conclusion: Developing strategies to address these needs can contribute to preventing tokenism and increase the acceptability and appropriateness of TB research. |
| dc.language.iso | eng |
| dc.publisher | Elsevier |
| dc.relation.ispartofseries | International Journal of Infectious Diseases;130(Suppl1) |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Tuberculosi - Tractament |
| dc.subject | Atenció centrada en el pacient |
| dc.subject | Participació comunitària |
| dc.subject.mesh | Tuberculosis |
| dc.subject.mesh | /drug therapy |
| dc.subject.mesh | Patient-Centered Care |
| dc.subject.mesh | Community Participation |
| dc.title | Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1016/j.ijid.2023.03.008 |
| dc.subject.decs | tuberculosis |
| dc.subject.decs | /farmacoterapia |
| dc.subject.decs | atención centrada en el paciente |
| dc.subject.decs | participación de la comunidad |
| dc.relation.publishversion | https://doi.org/10.1016/j.ijid.2023.03.008 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Saluzzo F] Vita-Salute San Raffaele University, Milan, Italy. Division of Immunology, Transplantation & Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. [Espinosa-Pereiro J] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Global Health Program from the Catalan Health Institute (PROSICS), Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Dressler S] EU-PEARL: EU Patient-cEntric clinicAl tRial pLatforms, WP5 – Integrated Research Platform for Tuberculosis (TB) Community Advisory Group, Berlin, Germany. [Tàvora Dos Santos Filho E] EU-PEARL: EU Patient-cEntric clinicAl tRial pLatforms, WP5 – Integrated Research Platform for Tuberculosis (TB) Community Advisory Group, Rio De Janeiro, Brazil. [Seidel S] Community Engagement and Stakeholder Relations, Global Alliance for TB Drug Development, New York, USA. [Gonzalez Moreno J] Janssen-Cilag S.A. Spain, Part of Janssen Pharmaceutical Companies, Madrid, Spain. [Sanchez-Montalva A] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Global Health Program from the Catalan Health Institute (PROSICS), Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Mycobacterial Infection Study Group from the Spanish Society of Clinical Microbiology and Infectious Diseases (GEIM-SEIMC), Barcelona, Spain |
| dc.identifier.pmid | 36906120 |
| dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/853966 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |